SeqNMA: sequential network meta-analysis with monitoring boundaries — a methods and software demonstration on a synthetic network
Abstract
Background: Trial sequential analysis (TSA) applies group-sequential monitoring boundaries to a single cumulative pairwise meta-analysis, controlling type-I error as evidence accrues. Sequential monitoring has been extended to network meta-analysis (NMA) so that a network estimate can be declared conclusive once its cumulative z-score crosses an appended boundary (Nikolakopoulou et al., 2018). SeqNMA is an open, browser-based implementation of that idea, intended as a teaching and prototyping tool.
Methods: An in-browser engine rebuilds a contrast-based random-effects NMA at each chronological study addition. For every pairwise comparison it computes a required information size from the heterogeneity-adjusted diversity design effect D\xc2\xb2 (Wetterslev et al., 2009; the diversity, not the cluster, design effect), and monitors the cumulative network z-score against an O'Brien-Fleming alpha-spending efficacy boundary z_k = z_\xce\xb1 / \xe2\x88\x9a(information fraction), Bonferroni-corrected across all T(T\xe2\x88\x921)/2 comparisons, with a non-binding beta-spending futility wedge. The boundary mathematics were independently re-derived and numerically confirmed.
Results (illustrative, synthetic): On a deliberately synthetic, reproducibly seeded 12-study network of four treatments, the A-versus-C comparison crosses its monitoring boundary after study 10 (cumulative z = 3.34, log-odds-ratio 0.40), while A-versus-D remains inconclusive at 66% of its required information (z = 0.63). These numbers demonstrate the machinery; they are not an empirical finding about any treatment.
Conclusions: Browser-based sequential NMA makes accumulating-evidence monitoring transparent and reproducible. Two limitations are essential: the method ASSUMES but does not TEST network consistency (no design-by-treatment interaction or node-splitting), so every crossing is valid only if direct and indirect evidence agree; and the worked example is synthetic, a software demonstration rather than evidence about real interventions.
References
Nikolakopoulou A, Mavridis D, Egger M, Salanti G. Continuously updated network meta-analysis and statistical monitoring for timely decision-making. Stat Methods Med Res. 2018;27(5):1312–1330. doi:10.1177/0962280216659896
Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009;9:86. doi:10.1186/1471-2288-9-86
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75. doi:10.1016/j.jclinepi.2007.03.013
O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549–556.
Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659–663.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–3124. doi:10.1002/sim.1875
Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7–8):932–944. doi:10.1002/sim.3767
Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2):98–110. doi:10.1002/jrsm.1044
Published
Issue
Section
License
Copyright (c) 2026 The Author

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles in Synthesis are published under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Authors retain copyright.